MedTrace Logo

O-GlcNAcylation Induced HMGB1 Signalling

NCT07702253 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-07-14

No results posted yet for this study

Summary

This study investigates how HMGB1 compartmentalisation and O-GlcNAcylation regulate inflammatory signalling, autophagy, and immune escape in cancer. Our research focuses on HMGB1, a key mediator of inflammation and immune regulation. Because extracellular HMGB1 and related cytokines are detectable in blood, circulating plasma biomarkers may serve as systemic surrogates of tumour-immune microenvironment (TIME) biology.

Spatial profiling technologies-such as multiplex immunofluorescence (mIF) and GeoMx Digital Spatial Profiling (DSP)-enable precise mapping of HMGB1 localisation, O-GlcNAcylation status, and immune cell organisation within tumour tissues. Integrating these spatial tissue features with plasma cytokine signatures provides a mechanistic and clinically translatable approach for recurrence prediction. This study aims to determine whether baseline and early-on-treatment plasma cytokine profiles can predict recurrence in patients with esophageal squamous cell carcinoma (ESCC), and to evaluate how these circulating immune mediators correspond to spatially resolved TIME features.

Conditions

  • Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

OTHER

specimen collection

Participants will contribute samples at one or more of the following clinically defined stages: Timepoint 1 - Baseline (diagnosis / pre-treatment) Specimens: 1. Tumor and adjacent biopsy obtained from diagnostic endoscopy * collect extra biopsy from diagnostic endoscopy * 4 biopsies for tumor and 4 biopsies for adjacent normal tissue, each approximately 3-5 mm in size 2. Peripheral blood (≤15 mL) for plasma and immune biomarkers Timepoint 2 - On-Treatment (early treatment) Specimens: 1. Peripheral blood (≤15 mL per time timepoint) 2. Tumor and adjacent biopsy only if clinically indicated (e.g., reassessment or surveillance endoscopy) Timepoint 3 - Recurrence / metastasis Specimens: 1. Biopsy of recurrent/metastatic lesion and adjacent tissue, if performed as part of routine clinical care 2. Peripheral blood (≤15 mL) obtained at the recurrence evaluation timepoint

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2036-03-31
Completion
2037-03-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07702253 on ClinicalTrials.gov